乌鸦传媒

<乌鸦传媒 class="page-title">Meeting Coverage

ASCO GI

<乌鸦传媒 class="page-description">American Society of Clinical Oncology
The Gastrointestinal Cancers Symposium
ASCO GI: Targeted Agent Slows Neuroendocrine Tumors

ORLANDO -- Patients with progressive pancreatic neuroendocrine tumors lived twice as long without progression when treated with sunitinib (Sutent) compared with placebo, data from a French clinical trial showed.

image
<乌鸦传媒 class="section_title">Latest ASCO GI Meeting Coverage
ASCO GI: Avastin Gives No Survival Advantage in Advanced Pancreatic Cancer

ORLANDO -- The addition of Avastin (bevacizumab) to Gemzar (gemcitabine) did not improve survival of advanced pancreatic cancer in a randomized trial, researchers here reported.

January 22, 2007
<乌鸦传媒 class="section_title"> Latest Oncology/Hematology Meeting Coverage